Neopharm news from FierceBiotech

Osprey Pharmaceuticals has appointed Jack M. Anthony as CEO. Dr. Philip Coggins, who previously held the position of CEO, will continue as president and assume the new role of chief science officer. Read more...

Here's wishing everyone had a happy holiday break.

While we were away for our customary leave, we spotted some notable headlines. Telik scored the biggest news of the past week, reporting that its cancer therapy …

Read more...

The launch of FierceBiotech's website--FierceBiotech.com--has met with a considerable amount of success. Of all of the FierceMarkets sites, …

Read more...

NeoPharm was also dealing with the ugly aftermath of its own trial failure this morning. Its stock plunged more than 70 percent after the company announced that its experimental therapy for malignant tumors of the central nervous system had failed a Phase III trial, failing to prove more effective than an existing therapy. Officials will also ponder the fate of cintredekin besudotox with regulators and researchers.

"Top-line data suggests that cintredekin besudotox, while …

Read more...

Shares of Neopharm have been swelling in recent months as the biotech draws closer to gathering the final data in its late-stage trial of its brain tumor shrinking therapy IL-13 (cintredekin besudotox). An independent committee has recommended that the trial continue until 215 of the 300 volunteers in it die, a figure that could be reached in three months. Following that point, Neopharm will determine when it will file for FDA approval. If it wins approval, Neopharm indicates that it will …

Read more...

Syntaxin has named Patrick James Doyle CEO. Doyle joins Syntaxin from Metabolex, California, where he held the post of chief corporate development.

Cipher Pharmaceuticals has promoted its president, Larry Andrews, to CEO. He replaces, John Mull, who will stay on as chairman.

MGI PHARMA has named …

Read more...

In a move that caught most observers by surprise, Digene CEO and founder Evan Jones said he plans to retire after 16 years at the helm. Digene is profitable and has been developing a test that identifies the virus that causes cervical cancer. His successor will be recruited from outside the company.

Isolagen has named Nicholas …

Read more...

Contract drug manufacturer Patheon has announced that Robert Tedford has turned in his resignation 10 months ahead of schedule. Patheon chairman Peter Green, president and CEO Nick DiPietro, and CFO and executive vice-president Douglas Ludwig have formed the "office of the chief …

Read more...

NeoPharm of Waukegan, IL announced late Friday that it was cutting about a quarter of its workforce in a wider effort to reduce expenses by $7 million a year. NeoPharm also said it was concentrating its workers in its headquarters and reprioritizing "the NeoLipid development program to reflect the changing market landscape and regulatory requirements." Just last week NeoPharm had touted the survival data of a study of its experimental drug for reducing the size of brain tumors. At least …

Read more...

> NeoPharm says the FDA has requested that it undertake a new clinical trial to support its application for approval of a new formulation of the cancer drug liposomal paclitaxel. Report

> The Garvan Institute of Medical Research in Australia has found a new antibody for inflammatory diseases and that Novo Nordisk had agreed to provide up to $100 million to take it …

Read more...